Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Su Yung‐Yeh, Emanuela Dell’Aquila et al.|Liver International|2025Cited by 10
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The <scp>MAGIC</scp> ‐D IndexMara Persano, Lorenzo Fornaro, Margherita Rimini et al.|Liver International|2025Cited by 9
Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironmentFrancesca Lodi, Diether Lambrechts, Sam Vanmassenhove et al.|Cell Reports Medicine|2025Cited by 7
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational studyMargherita Rimini, Daniele Lavacchi, Lorenzo Fornaro et al.|International Journal of Cancer|2025Cited by 4
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide populationMargherita Rimini, Daniele Lavacchi, Lorenzo Fornaro et al.|JNCI Journal of the National Cancer Institute|2025Cited by 4